Related Experiment Videos
Autoimmunity to collagen in human lung cancer
F Fernandez-Madrid1, R L Karvonen, M J Kraut
1Wayne State University School of Medicine, Department of Internal Medicine, Detroit, Michigan 48201, USA.
Cancer Research
|January 1, 1996
Summary
Autoantibodies targeting fibrillar collagen are common in lung cancer patients. Their levels correlate with cancer cell type and treatment response duration, suggesting a role in disease progression.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Autoantibodies are observed in cancer patients and animal models.
- Extracellular matrix components like collagen are crucial in tumor invasion.
- Collagen types I, III, and IV are key extracellular matrix constituents.
Purpose of the Study:
- To investigate the presence of autoimmunity to collagen antigens in lung cancer.
- To determine if anticollagen antibody levels correlate with clinical parameters in lung cancer patients.
Main Methods:
- Sera from 67 lung cancer patients and 50 controls were analyzed for antibodies against human collagen types I-V and aggrecan proteoglycan using ELISA.
- Statistical analyses, including multiple regression and discriminant function analyses, were employed to assess relationships between antibody levels and clinical data.
Main Results:
- Lung cancer patients frequently exhibited higher serum levels of antibodies against fibrillar collagen types I-III and V compared to controls (43.2% positive).
- Antibodies against aggrecan proteoglycan showed no significant difference between patients and controls.
- Serum antibody levels to collagen types IV and V were associated with progression-free survival, overall survival, and treatment response duration.
- Histological cell type, particularly small cell carcinoma, correlated with specific collagen antibody levels (lower for type IV, higher for type V).
- Smoking history (pack-years) was linked to antibody levels against type V collagen.
Conclusions:
- Autoantibodies to fibrillar collagen antigens are prevalent in lung cancer.
- The levels of these autoantibodies may serve as potential biomarkers, correlating with histological cell type and influencing treatment response duration.